Poseida Therapeutics to Present at Upcoming Virtual Investor Conferences
Poseida Therapeutics (Nasdaq: PSTX), a clinical-stage biopharmaceutical company, announced its participation in upcoming virtual investor conferences. The H. C. Wainwright 23rd Annual Global Investment Conference will feature an on-demand session starting September 13, 2021, at 7:00 am ET. Additionally, the Cantor Fitzgerald Global Healthcare Conference is scheduled for September 27, 2021, at 8:40 am ET. Webcasts will be available on Poseida's website, with replays accessible for 30 days. Poseida aims to develop innovative cell and gene therapeutics using its proprietary genetic engineering platforms.
- None.
- None.
SAN DIEGO, Sept. 7, 2021 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced that the Company will participate in the following upcoming virtual investor conferences:
H. C. Wainwright 23rd Annual Global Investment Conference
Date: On-demand session opens Monday, September 13, 2021
Time: 7:00am ET
Cantor Fitzgerald Global Healthcare Conference
Date: Monday, September 27, 2021
Time: 8:40am ET
Webcasts will be available on the Investors & Media Section of the Poseida website, www.poseida.com. An archived replay of each webcast will be available for approximately 30 days following each presentation.
About Poseida Therapeutics, Inc.
Poseida Therapeutics is a clinical-stage biopharmaceutical company dedicated to utilizing our proprietary genetic engineering platform technologies to create next generation cell and gene therapeutics with the capacity to cure. We have discovered and are developing a broad portfolio of product candidates in a variety of indications based on our core proprietary platforms, including our non-viral piggyBac DNA Modification System, Cas-CLOVER™ site-specific gene editing system and nanoparticle- and AAV-based gene delivery technologies. Our core platform technologies have utility, either alone or in combination, across many cell and gene therapeutic modalities and enable us to engineer our wholly-owned portfolio of product candidates that are designed to overcome the primary limitations of current generation cell and gene therapeutics. To learn more, visit www.poseida.com and connect with us on Twitter and LinkedIn.
Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding the clinical data presented, the potential benefits of Poseida's technology platforms and product candidates and Poseida's plans and strategy with respect to developing its technologies and product candidates. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon Poseida's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks and uncertainties associated with development and regulatory approval of novel product candidates in the biopharmaceutical industry, the fact that future clinical results could be inconsistent with results observed to date and the other risks described in Poseida's filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Poseida undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.
View original content to download multimedia:https://www.prnewswire.com/news-releases/poseida-therapeutics-to-present-at-upcoming-virtual-investor-conferences-301369282.html
SOURCE Poseida Therapeutics, Inc.
FAQ
When will Poseida Therapeutics participate in the H. C. Wainwright conference?
What date is the Cantor Fitzgerald Global Healthcare Conference?
How can I access the webcasts for Poseida's investor presentations?
What technologies does Poseida Therapeutics use for its therapeutics?
What is the focus of Poseida Therapeutics?
